Claims
- 1. A pharmaceutical composition comprising an anti-Toll-like Receptor, selected from the group consisting of Toll-like receptor 9 (TLR9) and Toll-like receptor 10 (TLR10), antibody specific for cells that cause a disease selected from the group consisting of B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin's Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, solid phase cancer, autoimmune disorder, and rejection of transplanted tissues or organs, wherein said antibody specifically binds to a polypeptide having an amino acid sequence of SEQ ID NO: 4 or amino acid 20 to amino acid 811 of SEQ ID NO: 4.
- 2. The pharmaceutical composition of claim 1, wherein said antibody is a monoclonal anti-TLR9 antibody or fragment thereof.
- 3. The pharmaceutical composition of claim 1, wherein said antibody is a monoclonal anti-TLR10 antibody or fragment thereof.
- 4. The pharmaceutical composition of claim 1, wherein said antibody is administered in an amount effective to kill or inhibit the growth of cells that cause a disease selected from the group consisting of B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin's Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, solid phase cancer, autoimmune disorder, and rejection of transplanted tissues or organs.
- 5. A method of targeting a TLR protein selected from the group consisting of TLR9 and TLR10, on cells that cause disease selected from the group consisting of B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin's Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, solid phase cancer, autoimmune disorder, and rejection of transplanted tissues or organs, comprising the step of administering a composition to said cells in an amount effective to target said TLR-expressing cells, wherein said composition is an anti-TLR antibody that specifically binds to a polypeptide selected from the group consisting of having an amino acid sequence of SEQ ID NO: 2, amino acid 25 to amino acid 811 of SEQ ID NO: 2, SEQ ID NO: 4, and amino acid 20 to amino acid 811 of SEQ ID NO: 4.
- 6. A method of killing or inhibiting the growth of TLR-expressing cells, selected from the group of TLR9 and TLR10, that cause disease selected from the group consisting of B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin's Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, solid phase cancer, autoimmune disorder, and rejection of transplanted tissues or organs, comprising the step of administering a composition to said cells in an amount effective to kill or inhibit the growth of said cells, wherein said composition is an anti-TLR antibody that specifically binds to a polypeptide selected from the group consisting of having an amino acid sequence of SEQ ID NO: 2, amino acid 25 to amino acid 818 of SEQ ID NO: 2, SEQ ID. NO: 4, and amino acid 20 to amino acid 811 of SEQ ID NO: 4.
- 7. A method of killing or inhibiting the growth of TLR-expressing cells, selected from the group of TLR9 and TLR10, that cause a disease selected from the group consisting of B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin's Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, solid phase cancer, autoimmune disorder, and rejection of transplanted tissues or organs, comprising the step of administering a vaccine to said cells in an amount effective to kill or inhibit the growth of said cancer cells, wherein said vaccine comprises a TLR polypeptide selected from the group consisting of having an amino acid sequence of SEQ ID NO: 2, amino acid 25 to amino acid 811 of SEQ ID NO: 2, SEQ ID NO: 4, and amino acid 20 to amino acid 811 of SEQ ID NO: 4, or immunogenic fragment thereof.
- 8. A method of killing or inhibiting the growth of TLR-expressing cells, selected from the group consisting of TLR9 and TLR10, that cause a disease selected from the group consisting of B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin's Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, solid phase cancer, autoimmune disorder, and rejection of transplanted tissues or organs, comprising the step of administering a composition to said cells in an amount effective to kill or inhibit the growth of said cells, wherein said composition comprises a nucleic acid selected from the group consisting of SEQ ID NO: 1 encoding TLR9, and SEQ ID NO: 3 encoding TLR10, or immunogenic fragment thereof, within a recombinant vector.
- 9. A method of killing or inhibiting the growth of TLR-expressing cells, selected from the group consisting of TLR9 and TLR10, that cause a disease selected from the group consisting of B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin's Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, solid phase cancer, autoimmune disorder, and rejection of transplanted tissues or organs, comprising the step of administering a composition to said cells in an amount effective to kill or inhibit the growth of said cells, wherein said composition comprises an antigen-presenting cell comprising a nucleic acid selected from the group consisting of SEQ ID NO: 1 encoding TLR9, and SEQ ID NO: 3 encoding TLR10, or immunogenic fragment thereof, within a recombinant vector.
- 10. The method according to any one of claims 5-9, wherein said cells are contacted with as second therapeutic agent.
- 11. The method according to any of claims 5-6, wherein said anti-TLR antibody composition is administered in an amount effective to achieve a dosage range from about 0.1 to about 10 mg/kg body weight.
- 12. The method according to any one of claims 5-9, wherein said pharmaceutical composition is administered in a sterile preparation together with a pharmaceutically acceptable carrier therefore.
- 13. A method of diagnosing a disease selected from the group consisting of B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin's Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, solid phase cancer, autoimmune disorder, and rejection of transplanted tissues or organscomprising the steps of:
(a) detecting or measuring the expression of TLR protein, selected from the group consisting of TLR9 and TLR10 on a cell; and (b) comparing said expression to a standard indicative of said disease.
- 14. The method according to claim 13, wherein said expression is TLR9 mRNA expression.
- 15. The method according to claim 13, wherein said expression is TLR10 mRNA expression.
- 16. The method according to claim 13, wherein said expression is detected or measured using anti-TLR9 antibodies.
- 17. The method according to claim 13, wherein said expression is detected or measured using anti-TLR10 antibodies.
- 18. Use of an anti-TLR antibody, selected from the group consisting of anti-TLR9 and anti-TLR10, in preparation of a medicament for killing or inhibiting the growth of TLR9- or TLR10-expressing cells that cause a disease selected from the group consisting of B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin's Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, solid phase cancer, autoimmune disorder, and rejection of transplanted tissues or organs, wherein said antibody specifically binds to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 2, amino acid 25 to amino acid 818 of SEQ ID NO: 2, SEQ ID NO: 4, and amino acid 20 to amino acid 811 of SEQ ID NO: 4.
- 19. Use of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, amino acid 25 to amino acid 818 of SEQ ID NO: 2, SEQ ID NO: 4, and amino acid 20 to amino acid 811 of SEQ ID NO: 4 in preparation of a vaccine for killing or inhibiting the growth of TLR9- or TLR10-expressing cells that cause a disease selected from the group consisting of B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin's Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, solid phase cancer, autoimmune disorder, and rejection of transplanted tissues or organs.
- 20. Use of a nucleic acid selected from the group consisting of SEQ ID NO: 1 encoding TLR9, and SEQ ID NO: 3 encoding TLR10, or immunogenic fragment thereof, within a recombinant vector, in preparation of a medicament for killing or inhibiting the growth of TLR9- or TLR10-expressing cells that cause a disease selected from the group consisting of B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin's Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, solid phase cancer, autoimmune disorder, and rejection of transplanted tissues or organs.
- 21. Use of an antigen-presenting cell comprising a nucleic acid selected from the group consisting of SEQ ID NO: 1 encoding TLR9, and SEQ ID NO: 3 encoding TLR10 or immunogenic fragment thereof, within a recombinant vector, in preparation of a medicament for killing or inhibiting the growth of TLR9- or TLR10-expressing cells that cause a disease selected from the group consisting of B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin's Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, solid phase cancer, autoimmune disorder, and rejection of transplanted tissues or organs.
- 22. An antibody that specifically binds to a polypeptide selected from the group consisting of having the amino acid sequence of SEQ ID NO: 2, amino acid 25 to amino acid 818 of SEQ ID NO: 2, SEQ ID NO: 4, and amino acid 20 to amino acid 811 of SEQ ID NO: 4.
- 23. The antibody of claim 22, wherein said antibody is a monoclonal anti-TLR9 antibody or fragment thereof.
- 24. The antibody of claim 22, wherein said antibody is a monoclonal anti-TLR10 antibody or fragment thereof.
- 25. The antibody of claim 22, wherein said antibody is labeled with a radioisotope.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part application of U.S. application Ser. No. 10/302,444 filed on Nov. 22, 2002, entitled “Methods of Therapy and Diagnosis Using Targeting of Cells that Express Toll-like Receptor Proteins,” Attorney Docket No. HYS-49CP, which in turn is a continuation-in-part application of U.S. application Ser. No. 10/077,676 filed on Feb. 14, 2002, entitled “Methods of Therapy and Diagnosis Using Targeting of Cells that Expressing Toll-Like Receptor 9 Protein”, Attorney Docket No. HYS-49, which in turn is a continuation-in-part application of U.S. application Ser. No. 09/687,527 filed on Oct. 12, 2000, entitled “Full Length Novel Nucleic Acids and Polypeptides”, Attorney Docket No. 795, and U.S. application Ser. No. 09/488,725 filed on Jan. 21, 2000, entitled “Novel Contigs Obtained from Various Libraries,” Attorney Docket No. 784. This and all other U.S. Patents and Patent Applications cited herein are hereby incorporated by reference in their entirety.
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
10302444 |
Nov 2002 |
US |
Child |
10327491 |
Dec 2002 |
US |
Parent |
10077676 |
Feb 2002 |
US |
Child |
10302444 |
Nov 2002 |
US |
Parent |
09687527 |
Oct 2000 |
US |
Child |
10077676 |
Feb 2002 |
US |
Parent |
09488725 |
Jan 2000 |
US |
Child |
10077676 |
Feb 2002 |
US |